depression and other anxiety-related disorders.4 In 2004,
sertraline was the ninth top-selling drug worldwide ($3.36
billion).5 (þ)-Sertraline has become a popular target for
asymmetric synthesis due to its small but challenging
structure.6
protodeboronation leads to the tertiary stereogenic center.
These processes have been found to be highly stereo-
selective, occurring with retention of stereochemistry in
the lithiation/borylation reaction2 and again retention
of stereochemistry in the protodeboronation reaction.3
The related molecule, (þ)-indatraline (2), is a potent
psychoactive compound that acts as a monoamine reup-
take inhibitor and affects the dopamine and the serotonin
transporter.7 To date, only three asymmetric syntheses of
trans (þ)/(ꢀ)-2 have been reported.8
Scheme 2. Synthesis of Olefin 3 via Lithiation/Borylationꢀ
Protodeboronation Sequencea
Scheme 1. Retrosynthetic Scheme for the Synthesis of Sertraline
(1) and Indatraline (2)a
a Cb = 2,2-diisopropylcarbamoyl, pin = pinacolato.
Our synthesis began with commercially available homo-
allylic alcohol 7, a substrate which can also be prepared in
98% ee either by enzymatic resolution of the racemate9 or
by asymmetric allylation of benzaldehyde using the (R,R)-
Leighton reagent.10 The secondary alcohol 7 was initially
converted into chiral carbamate 4 in 83% yield (Scheme 2).
Thereafter, carbamate 4 was subjected to the lithiation/
borylation reaction by treatment with 1.3 equiv of sec-
butyllithium and a subsequent reaction with 1.5 equiv of
aryl pinacol boronic ester 5 (Table 1). The formation of a
boron-ate complex between 4 and 5 and its conversion to 6
was monitored by 11B NMR. However, under our stan-
dardreaction conditions, no1,2-migration occurred, either
upon warming to ambient temperature or even by heating
thereactionmixtureunderreflux(Table1, entry 1). The ate
complex stubbornly remained.
To determine whether the problem was related to steric
effects, the related propylcarbamate 8 was tested in the
lithiation/borylation reaction and this led to the homo-
logated boronic ester 9 in 72% yield and 99% es under
standard conditions (Scheme 3). Like previous extensive
examples,2 the 1,2-migration occurred simply upon warm-
ing fromꢀ78°C toambient temperature. This showed that
the problem was not steric in origin.
a Cb = 2,2-diisopropylcarbamoyl, pin = pinacolato.
Our retrosynthetic analysis of both (þ)-sertraline and
(þ)-indatraline led us toacommonprecursor, diarylalkene
3 (Scheme 1). We envisaged that this intermediate could be
obtained from our recently reported methodology of
lithiation/borylationꢀprotodeboronation using carba-
mate 4 and boronic ester 5.2,3 This reaction sequence
occurs via an intermediate boron-ate complex, which
undergoes a stereospecific 1,2-metalate rearrangement to
afford a homologated tertiary boronic ester 6. Subsequent
(4) (a) Koe, K. B.; Weisman, A.; Welch, W. M.; Broune, R. G. J.
Pharmacol. Exp. Ther. 1983, 226, 686–700. (b) Welch, W. M.; Kraska,
A. R.; Sarges, R.; Koe, K. B. J. Med. Chem. 1984, 27, 1508–1515.
(5) Maggon, K. Drug Discovery Today 2005, 10, 739–742.
(6) For recent asymmetric examples (2005ꢀpresent), see: (a) Dockendorff,
C; Sahli, S.; Olsen, M.; Milhau, L.; Lautens, M. J. Am. Chem. Soc. 2005,
127, 15028–15029. (b) Wang, G.; Zheng, C.; Zhao, G. Tetrahedron:
Asymmetry 2006, 17, 2074–2081. (c) Han, Z.; Wang, Z.; Zhang, X.;
Ding, K. Angew. Chem., Int. Ed. 2009, 48, 5345–5349. (d) Ohmiya, H.;
Makida, Y.; Li, D.; Tanabe, M.; Sawamura, M. J. Am. Chem. Soc. 2010,
132, 879–889. (e) Garcia, A. E.; Ouizem, S.; Cheng, X.; Romanens, P.;
These initial results indicated that the alkene was inter-
fering in the lithiation/borylation process, and we consid-
ered the possibility that a Liꢀπ coordination complex may
be forming (B, Figure 2),11 which would stabilize the ate
complex. In this complex, 1,2-metalate rearrangement
would be disfavored as the migrating group is not aligned
€
Kundig, E. P. Adv. Synth. Catal. 2010, 352, 2306–2314. (f) Krumlinde,
€
P.; Bogar, K.; Backvall, J. E. Chem.;Eur. J. 2010, 16, 4031–4036. (g)
Chen, F.; Wang, T.; He, Y.; Ding, Z.; Li, Z.; Xu, L.; Fan, Q. H. Chem.;
Eur. J. 2011, 17, 1109–1113. (h) Barluenga, J.; Florentino, L.; Aznar, F.;
ꢀ
Valdes, C. Org. Lett. 2011, 13, 510–513.
(9) Master, H. E.; Nevadkar, R. V.; Rane, R. A.; Kumar, A.
Tetrahedron Lett. 1996, 37, 9253–9254.
(10) (a) Kubota, K.; Leighton, J. L. Angew. Chem., Int. Ed. 2003, 42,
946–948. (b) Kim, H.; Ho, S.; Leighton, J. L. J. Am. Chem. Soc. 2011,
133, 6517–6520.
(11) Monje, P.; Paleo, M. R.; Garcıa-Rıo, L.; Sardina, F. J. J. Org.
Chem. 2008, 73, 7394–7397.
(7) (a) Bøgesø, K. P.; Christensen, A. V.; Hyttel, J.; Liljefors, T. J.
Med. Chem. 1985, 28, 1817–1828. (b) Hyttel, J.; Larsen, J. J. J.
Neurochem. 1985, 44, 1615–1622.
(8) Asymmetric indatraline syntheses: (a) Davies, H. M. L.; Gregg,
T. M. Tetrahedron Lett. 2002, 43, 4951–4953. (b) Yoo, K.; Kim, H.; Yun,
J. Chem.;Eur. J. 2009, 15, 11134–11138. (c) Taylor, J. C.; Correia,
C. R. D. J. Org. Chem. 2011, 76, 857–869.
Org. Lett., Vol. 13, No. 21, 2011
5741